Opus Genetics, Inc. IRD
4.76
(0.11)
(2.26%)
as of 25 Sep
- Market cap
- $405.2M
- P/E
- 0.0×
Follow IRD
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (4,796.52%) | 524.65% | (449.36%) | (338.75%) |
+8 more TTM periods Free account |
|
| (163.50%) | (186.04%) | (113.86%) | (178.28%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(126.21%) | (186.14%) | (116.79%) | (969.48%) | |
Average Days of Receivables |
38.55 | 52.73 | 51.29 | 72.74 | |
Free Cash Flow per Share |
(0.43) | (0.45) | (0.57) | (0.47) | |
Free Cash Flow |
(40.67) | (38.99) | (35.25) | (32.86) | |
Piotroski F-Score |
2.00 | 2.00 | 4.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(36.72%) | (276.05%) | (58.33%) | (86.81%) | |
Accounts Receivable Turnover |
4.44 | 4.98 | 5.11 | 6.13 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
391.85% | 279.03% | 217.05% | 378.72% | |
Selling, General and Administrative Expense of Revenue |
221.62% | 180.10% | 154.85% | 166.68% | |
Share Based Compensation of Revenue |
45.26% | 32.96% | 23.94% | 23.37% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.38 | 0.36 | 0.71 | 0.48 | |
Depreciation/Fixed assets |
0.31 | 0.28 | 0.27 | 0.24 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.10 | 0.14 | 0.23 | 0.21 | |
Operating CF per Share |
(0.43) | (0.45) | (0.57) | (0.47) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(1,091.82%) | (892.36%) | (349.33%) | (466.09%) |
Columns are period end dates